Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention

Abstract

Adenocarcinoma of the prostate remains a significant public health problem and a prevalent cancer in men. Prostate-specific antigen used as a biomarker has established a clear migration of patients towards earlier-stage disease at presentation. However, in spite of process improvements in traditional therapies including surgery, radiation therapy, and hormone management, there remains a significant cohort of patients with intermediate- to high-risk features for poor outcome in spite of optimal use of traditional management. This paper focuses on future treatment strategies integrating new therapeutic options with traditional management, specifically to pinpoint new radiation therapy strategies.

Keywords::

• Casodex^®
• IGF-IR
• integrin
• prostate cancer
• radiation therapy

Financial & competing interests disclosure

Support for this article was from NIH-RO1 CA-89720 and RO1 CA-109874. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.